BACKGROUND: Vaccine development in human Plasmodium falciparum malaria has been hampered by the exceptionally high levels of CD8(+) T cells required for efficacy. Use of potently immunogenic human adenoviruses as vaccine vectors could overcome this problem, but these are limited by preexisting immunity to human adenoviruses. METHODS: From 2007 to 2010, we undertook a phase I dose and route finding study of a new malaria vaccine, a replication-incompetent chimpanzee adenovirus 63 (ChAd63) enco...Expand abstract
- Publication status:
- Peer review status:
- Peer reviewed
- Publisher's version
- Oxford University Press Publisher's website
- The Journal of infectious diseases Journal website
- Publication date:
- Source identifiers:
- Local pid:
- Copyright holder:
- O’Hara et al.
- Copyright date:
- Copyright © 2012 O’Hara et al. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: firstname.lastname@example.org. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector.
If you are the owner of this record, you can report an update to it here: Report update to this record